158 related articles for article (PubMed ID: 35539052)
1. Apoferritin encapsulation of cysteine protease inhibitors for cathepsin L inhibition in cancer cells.
Quilles Junior JC; Carlos FDRR; Montanari A; Leitão A; Mignone VW; Arruda MA; Turyanska L; Bradshaw TD
RSC Adv; 2019 Nov; 9(63):36699-36706. PubMed ID: 35539052
[TBL] [Abstract][Full Text] [Related]
2. Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery.
Breen AF; Scurr D; Cassioli ML; Wells G; Thomas NR; Zhang J; Turyanska L; Bradshaw TD
Int J Nanomedicine; 2019; 14():9525-9534. PubMed ID: 31824148
[TBL] [Abstract][Full Text] [Related]
3. Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy.
Abuzaid H; Abdelrazig S; Ferreira L; Collins HM; Kim DH; Lim KH; Kam TS; Turyanska L; Bradshaw TD
ACS Omega; 2022 Jun; 7(25):21473-21482. PubMed ID: 35785302
[TBL] [Abstract][Full Text] [Related]
4. Delivery of Temozolomide and N3-Propargyl Analog to Brain Tumors Using an Apoferritin Nanocage.
Bouzinab K; Summers HS; Stevens MFG; Moody CJ; Thomas NR; Gershkovich P; Weston N; Ashford MB; Bradshaw TD; Turyanska L
ACS Appl Mater Interfaces; 2020 Mar; 12(11):12609-12617. PubMed ID: 32073826
[TBL] [Abstract][Full Text] [Related]
5. Development of novel apoferritin formulations for antitumour benzothiazoles.
Breen AF; Wells G; Turyanska L; Bradshaw TD
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1155. PubMed ID: 32721126
[TBL] [Abstract][Full Text] [Related]
6. Biological Activity and Physicochemical Properties of Dipeptidyl Nitrile Derivatives Against Pancreatic Ductal Adenocarcinoma Cells.
Quilles JC; Bernardi MDL; Batista PHJ; Silva SCM; Rocha CMR; Montanari CA; Leitão A
Anticancer Agents Med Chem; 2019; 19(1):112-120. PubMed ID: 30370859
[TBL] [Abstract][Full Text] [Related]
7. Apoferritin-encapsulated PbS quantum dots significantly inhibit growth of colorectal carcinoma cells.
Bradshaw TD; Junor M; Patanè A; Clarke P; Thomas NR; Li M; Mann S; Turyanska L
J Mater Chem B; 2013 Dec; 1(45):6254-6260. PubMed ID: 32261698
[TBL] [Abstract][Full Text] [Related]
8. An Apoferritin-Hemagglutinin Conjugate Vaccine with Encapsulated Nucleoprotein Antigen Peptide from Influenza Virus Confers Enhanced Cross Protection.
Wei J; Li Z; Yang Y; Ma G; Su Z; Zhang S
Bioconjug Chem; 2020 Aug; 31(8):1948-1959. PubMed ID: 32678574
[TBL] [Abstract][Full Text] [Related]
9. Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin.
Xing R; Wang X; Zhang C; Zhang Y; Wang Q; Yang Z; Guo Z
J Inorg Biochem; 2009 Jul; 103(7):1039-44. PubMed ID: 19501911
[TBL] [Abstract][Full Text] [Related]
10. Encapsulation of copper phenanthroline within horse spleen apoferritin: characterisation, cytotoxic activity and ability to retain temozolomide.
Cassioli ML; Fay M; Turyanska L; Bradshaw TD; Thomas NR; Pordea A
RSC Adv; 2024 Apr; 14(20):14008-14016. PubMed ID: 38686295
[TBL] [Abstract][Full Text] [Related]
11. The novel bovine serpin endopin 2C demonstrates selective inhibition of the cysteine protease cathepsin L compared to the serine protease elastase, in cross-class inhibition.
Hwang SR; Stoka V; Turk V; Hook VY
Biochemistry; 2005 May; 44(21):7757-67. PubMed ID: 15909990
[TBL] [Abstract][Full Text] [Related]
12. Differential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target.
Reinheckel T; Peters C; Krüger A; Turk B; Vasiljeva O
Front Pharmacol; 2012; 3():133. PubMed ID: 22798952
[TBL] [Abstract][Full Text] [Related]
13. Identification and characteristics of a cathepsin L-like cysteine protease from Clonorchis sinensis.
Ma C; Liang K; Tang L; He S; Liu X; He M; Li Y
Parasitol Res; 2019 Mar; 118(3):829-835. PubMed ID: 30689051
[TBL] [Abstract][Full Text] [Related]
14. A Self-Targeting, Dual ROS/pH-Responsive Apoferritin Nanocage for Spatiotemporally Controlled Drug Delivery to Breast Cancer.
Du B; Jia S; Wang Q; Ding X; Liu Y; Yao H; Zhou J
Biomacromolecules; 2018 Mar; 19(3):1026-1036. PubMed ID: 29455519
[TBL] [Abstract][Full Text] [Related]
15. Differential Cleaving of Specific Substrates for Cathepsin-Like Activity Shows Cysteine and Serine Protease Activities and a Differential Profile Between
Torralbo-Ramírez V; Molina-Fernández D; Malagón D; Benítez R; Adroher FJ
Foodborne Pathog Dis; 2019 Nov; 16(11):744-751. PubMed ID: 31215796
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.
Méthot N; Rubin J; Guay D; Beaulieu C; Ethier D; Reddy TJ; Riendeau D; Percival MD
J Biol Chem; 2007 Jul; 282(29):20836-46. PubMed ID: 17535802
[TBL] [Abstract][Full Text] [Related]
17. Prolonged pharmacological inhibition of cathepsin C results in elimination of neutrophil serine proteases.
Guarino C; Hamon Y; Croix C; Lamort AS; Dallet-Choisy S; Marchand-Adam S; Lesner A; Baranek T; Viaud-Massuard MC; Lauritzen C; Pedersen J; Heuzé-Vourc'h N; Si-Tahar M; Fıratlı E; Jenne DE; Gauthier F; Horwitz MS; Borregaard N; Korkmaz B
Biochem Pharmacol; 2017 May; 131():52-67. PubMed ID: 28193451
[TBL] [Abstract][Full Text] [Related]
18. Unexpected Activity of a Novel Kunitz-type Inhibitor: INHIBITION OF CYSTEINE PROTEASES BUT NOT SERINE PROTEASES.
Smith D; Tikhonova IG; Jewhurst HL; Drysdale OC; Dvořák J; Robinson MW; Cwiklinski K; Dalton JP
J Biol Chem; 2016 Sep; 291(37):19220-34. PubMed ID: 27422822
[TBL] [Abstract][Full Text] [Related]
19. Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents.
Massai L; Messori L; Micale N; Schirmeister T; Maes L; Fregona D; Cinellu MA; Gabbiani C
Biometals; 2017 Apr; 30(2):313-320. PubMed ID: 28283781
[TBL] [Abstract][Full Text] [Related]
20. 3-hydroxy-3-methylglutaryl coenzyme A reductase is sterol-dependently cleaved by cathepsin L-type cysteine protease in the isolated endoplasmic reticulum.
Moriyama T; Wada M; Urade R; Kito M; Katunuma N; Ogawa T; Simoni RD
Arch Biochem Biophys; 2001 Feb; 386(2):205-12. PubMed ID: 11368343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
